CRP and adiponectin and its oligomers in the metabolic syndrome - Evaluation of new laboratory-based biomarkers

被引:43
作者
Devaraj, Sridevi [1 ]
Swarbrick, Michael M. [2 ]
Singh, Uma [1 ]
Adams-Huet, Beverley [4 ]
Havel, Peter J. [2 ,3 ]
Jialal, Ishwarlal [1 ]
机构
[1] UC Davis Med Ctr, Lab Atherosclerosis & Metab Res, Sacramento, CA 95817 USA
[2] Univ Calif Davis, Dept Nutr, Sacramento, CA 95817 USA
[3] Univ Calif Davis, Dept Mol Biosci, Sch Vet Med, Sacramento, CA 95817 USA
[4] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
关键词
C-reactive protein; adiponectin; biomarker; metabolic syndrome;
D O I
10.1309/RN84K51B2JJY1Y0B
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The metabolic syndrome (MetS) confers an increased risk or diabetes and cardiovascular disease. Although high-sensitive C-reactive protein (hsCRP) concentrations are higher and adiponectin concentrations lower in MetS, there is no reliable biochemical measure that can capture its various features. We evaluated whether hsCRP, adiponectin, or the ratio of adiponectin or its oligomers, especially the high-molecular-weight (HMW) oligomer, to hsCRP predict MetS in 123 subjects with MetS compared with that in 91 healthy control subjects. MetS subjects had significantly higher hsCRP levels and lower total adiponectin and oligomer levels relative to control subjects (P < .0001). The HMW/total adiponectin and adiponectin/CRP ratios were significantly lower in MetS subjects than control subjects (P < .005). The odds ratio (OR) of MetS using the 75th percentile cutoff for CRP was 3.8 (95% confidence interval [CI], 2.1-68) and equivalent to low total adiponectin (OR, 2.5; 95% CI, 1.3-4.5), its oligomers, or the adiponectin/ hsCRP ratio (OR, 2.6; 95% CI, 1.5,4.8). Thus, measurements of CRP, adiponectin, or its oligomers provide robust biomarkers for predicting MetS.
引用
收藏
页码:815 / 822
页数:8
相关论文
共 40 条
[1]   Improvements in insulin resistance with weight loss, in contrast to rosiglitazone, are not associated with changes in plasma adiponectin or adiponectin multimeric complexes [J].
Abbasi, F ;
Chang, SA ;
Chu, JW ;
Ciaraldi, TP ;
Lamendola, C ;
McLaughlin, T ;
Reaven, GM ;
Reaven, PD .
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2006, 290 (01) :R139-R144
[2]   Plasma adiponectin concentrations do not increase in association with moderate weight loss in insulin-resistant, obese women [J].
Abbasi, F ;
Lamendola, C ;
McLaughlin, T ;
Hayden, J ;
Reaven, GM ;
Reaven, PD .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2004, 53 (03) :280-283
[3]   Metabolic syndrome, C-reactive protein, and prognosis in patients with established coronary artery disease [J].
Aguilar, David ;
Fisher, Marian R. ;
O'Connor, Christopher M. ;
Dunne, Michael W. ;
Muhlestein, Joseph B. ;
Yao, Louis ;
Gupta, Sandeep ;
Benner, Rebecca J. ;
Cook, Thomas D. ;
Edwards, Dearborn ;
Pfeffer, Marc A. .
AMERICAN HEART JOURNAL, 2006, 152 (02) :298-304
[4]   Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity [J].
Arita, Y ;
Kihara, S ;
Ouchi, N ;
Takahashi, M ;
Maeda, K ;
Miyagawa, J ;
Hotta, K ;
Shimomura, I ;
Nakamura, T ;
Miyaoka, K ;
Kuriyama, H ;
Nishida, M ;
Yamashita, S ;
Okubo, K ;
Matsubara, K ;
Muraguchi, M ;
Ohmoto, Y ;
Funahashi, T ;
Matsuzawa, Y .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 257 (01) :79-83
[5]   Selective downregulation of the high-molecular weight form of adiponectin in hyperinsulinemia and in type 2 diabetes - Differential regulation from nondiabetic subjects [J].
Basu, Rita ;
Pajvani, Utpal B. ;
Rizza, Robert A. ;
Scherer, Philipp E. .
DIABETES, 2007, 56 (08) :2174-2177
[6]   Changes of adiponectin oligomer composition by moderate weight reduction [J].
Bobbert, T ;
Rochlitz, H ;
Wegewitz, U ;
Akpulat, S ;
Mai, K ;
Weickert, MO ;
Möhlig, M ;
Pfeiffer, AFH ;
Spranger, J .
DIABETES, 2005, 54 (09) :2712-2719
[7]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[8]   C-reactive protein induces phosphorylation of insulin receptor substrate-1 on Ser307 and Ser612 in L6 myocytes, thereby impairing the insulin signalling pathway that promotes glucose transport [J].
D'Alessandris, C. ;
Lauro, R. ;
Presta, I. ;
Sesti, G. .
DIABETOLOGIA, 2007, 50 (04) :840-849
[9]   Defining the proinflammatory phenotype using high sensitive C-reactive protein levels as the biomarker [J].
Devaraj, S ;
O'Keefe, G ;
Jialal, I .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (08) :4549-4554
[10]   Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status [J].
Devaraj, S ;
Rosenson, RS ;
Jialal, I .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2004, 33 (02) :431-+